SWECARNET

SWECARNET brings together actors and competencies in the Swedish CAR T field, with the goal of implementing gene-modified immune effector cell therapy for patients throughout the country. The network is coordinated by Karolinska Institutet.

Karolinska Institutet, Karolinska University Hospital, Uppsala University, Uppsala University Hospital, Lund University, Skåne University Hospital, University of Gothenburg, Sahlgrenska University Hospital, Linköping University, University Hospital in Linköping, University Hospital of Umeå, Lif – The researching pharmaceutical companies, Bristol Myers Squibb (BMS), Novartis Sverige, Janssen Cilag, Gilead Sciences.

The first CAR T to be manufactured in Sweden (and Europe) was in 2014 and the first Standard of Care use of a commercial CAR T was in 2019. There are now several treatment centres in Sweden and several products have been administered in clinical trial and/or standard of care. SWECARNET collects information direct from treating clinicians to map the use of CAR T in Sweden. 

CAR-T therapy is a new type of immunotherapy that has revolutionized cancer care. In simple terms, the treatment involves reprogramming the immune system's T cells (white blood cells) so that they can more effectively identify and destroy tumor cells.